NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

NewAmsterdam Pharma (Nasdaq:NAMS) announced inducement stock option grants for a newly hired non-executive employee under the 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The Compensation Committee approved options covering 20,000 ordinary shares with an exercise price of $35.20 per share, equal to the closing Nasdaq price on January 2, 2026. The options vest over four years: 25% on the one-year anniversary of the vesting commencement date, then the remaining shares in 36 equal monthly installments, subject to continued service, and are governed by the 2024 Inducement Plan and an option award agreement.

Key Figures

Inducement options 20,000 shares Aggregate options granted to one non‑executive new hire

Exercise price $35.20 per share Set at Jan 2, 2026 Nasdaq closing price on grant date

Vesting period 4 years Options vest over four years subject to continued service

Initial vesting 25% after 1 year 25% of shares vest on one‑year anniversary of vesting start

Monthly installments 36 installments Remaining 75% vests in 36 equal monthly installments

Market Reality Check

$34.37 Last Close

Volume Volume 991,009 vs 20‑day average 954,998 (relative volume 1.04x) shows typical trading activity. normal

Technical Shares at $35.20 are trading above the 200‑day MA of $26.18 and 16.19% below the $42.00 52‑week high.

Peers on Argus

Peers showed mixed moves: RARE +3.33%, APLS +3.07%, CRNX +0.24% versus VKTX -0.29% and MLYS -1.46%, indicating stock‑specific rather than broad sector momentum for NAMS.

Common Catalyst Select peers had news-driven activity, including a clinical trial update (CRNX) and a conference participation announcement (APLS).

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 05	Inducement grants	Neutral	+1.4%	Announced inducement options for 40,000 shares to two new hires.
Nov 25	Investor conferences	Neutral	+2.9%	Planned participation in three December 2025 investor conferences.
Nov 07	Inducement grants	Neutral	+6.0%	Inducement options on 18,000 shares for a non‑executive hire.
Nov 05	Earnings update	Positive	+4.4%	Q3 2025 financials and obicetrapib development and regulatory update.
Oct 30	Medical meetings	Positive	+8.1%	Planned presentations of Phase 3 trial data and multiple conferences.

Pattern Detected

Recent news, including option inducement grants, conferences, and earnings/corporate updates, has generally coincided with positive next‑day price reactions.

Recent Company History

Over the last few months, NewAmsterdam issued several updates spanning inducement grants, investor conferences, and a Q3 2025 results and corporate update. Inducement grant announcements on Nov 7, 2025 and Dec 5, 2025, plus multiple conference participations, all saw positive 24‑hour price moves from 4.37% up to 8.05%. The Q3 update highlighted cash of $756.0M and ongoing development of obicetrapib. Today’s additional inducement grant continues this pattern of routine corporate and compensation disclosures.

Market Pulse Summary

This announcement details a targeted inducement option grant covering 20,000 shares at an exercise price of $35.20, vesting over four years under the 2024 Inducement Plan and Nasdaq Listing Rule 5635(c)(4). It follows prior similar grants and routine corporate updates that have accompanied positive price moves. Investors monitoring NewAmsterdam may focus more closely on future clinical, regulatory, and financial milestones, while noting the stock’s position above its 200‑day MA and below its 52‑week high.

Key Terms

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

ldl-c medical

"with elevated low-density lipoprotein cholesterol (“LDL-C”)"

LDL-C stands for low-density lipoprotein cholesterol, the portion of cholesterol carried in the blood by LDL particles that is commonly linked to buildup of plaque in arteries—think of it like sticky debris that can clog pipes. Investors care because changes in LDL-C are a key measure used by regulators and clinicians to judge the effectiveness of cardiovascular drugs and devices, shape insurance coverage, and influence market demand for treatments that lower heart attack and stroke risk.

cardiovascular disease medical

"for patients at risk of cardiovascular disease (“CVD”)"

A group of conditions that affect the heart and blood vessels, such as heart attacks, strokes and clogged arteries. Think of the cardiovascular system as a body’s plumbing and engine: when pipes narrow or the pump fails, treatment, devices and long-term care become necessary. Investors watch these diseases because their prevalence drives demand for drugs, devices and services, influences healthcare costs and insurer payouts, and affects workforce productivity and regulatory risk.

exercise price financial

"The share options have an exercise price per share equal to $35.20"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The shares subject to the options will vest over four years"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

option award agreement financial

"the terms and conditions of an option award agreement covering the grant."

A written contract that grants an individual the right to buy company shares at a set price under specific conditions, like how many options they get, when they can exercise them, and when they expire. Think of it like a ticket that becomes valid only after certain milestones; it matters to investors because these agreements affect how many shares may enter the market, management incentives, and a company’s future earnings per share and dilution.

AI-generated analysis. Not financial advice.

NAARDEN, the Netherlands and MIAMI, Jan. 05, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 20,000 of NewAmsterdam’s ordinary shares to one non-executive new hire. The share options were granted as an inducement material to the employee’s acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).

The share options have an exercise price per share equal to $35.20, which represents the closing market price on the Nasdaq Stock Market of the Company’s ordinary shares on January 2, 2026, the grant date. The shares subject to the options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 equal monthly installments thereafter, subject to the employee’s continued service with NewAmsterdam on such vesting dates. The options are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of an option award agreement covering the grant.

About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com

FAQ

What did NewAmsterdam (NAMS) announce on January 5, 2026 regarding option grants?

NewAmsterdam announced inducement options covering 20,000 shares granted to one non-executive new hire under the 2024 Inducement Plan.

What is the exercise price and grant date for the NAMS inducement options?

The exercise price is $35.20 per share, equal to the closing Nasdaq price on the grant date of January 2, 2026.

How do the NewAmsterdam (NAMS) options vest and what is the vesting schedule?

Options vest over four years: 25% at the one-year anniversary and the remainder in 36 equal monthly installments, subject to continued service.

Under which Nasdaq rule were the NewAmsterdam (NAMS) inducement awards approved?

The awards were approved pursuant to Nasdaq Listing Rule 5635(c)(4), which covers inducement grants for newly hired employees.

Who approved the inducement option grant at NewAmsterdam (NAMS)?

The Compensation Committee of NewAmsterdam’s Board of Directors approved the grant.

Are the NAMS inducement options subject to additional terms or agreements?

Yes, the options are subject to the terms of the 2024 Inducement Plan and an individual option award agreement.